Evidence map›Paper›PMID 40872743›Full record

ArticleViruses2025

4-Hydroxychalcone Inhibits Human Coronavirus HCoV-OC43 by Targeting EGFR/AKT/ERK1/2 Signaling Pathway.

Yuanyuan Huang, Jieyu Li, Qiting Luo, Yuexiang Dai, Xinyi Luo, Jiapeng Xu, Wei Ye, Xinrui Zhou, Jiayi Diao, Zhe Ren and 5 more

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuanyuan HuangSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Jieyu LiSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Qiting LuoCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Yuexiang DaiSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Xinyi LuoCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Jiapeng XuCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Wei YeCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Xinrui ZhouCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Jiayi DiaoCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Zhe RenGuangdong Province Key Laboratory of Bioengineering Medicine, Key Laboratory of Innovative Technology Research on Natural Products and Cosmetics Raw Materials, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.ORCID 0000-0001-7573-5288
Ge LiuCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Zhendan HeCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Zhiping WangSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Yifei WangSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Qinchang ZhuCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.

Funding

Shenzhen Science and Technology Innovation Commission JCYJ20220530153206014
6 · The paper itself

Abstract

Human coronaviruses are a group of viruses that continue to threaten human health. In this study, we investigated the antiviral activity of 4-hydroxychalcone (4HCH), a chalcone derivative, against human coronavirus HCoV-OC43. We found that 4HCH significantly inhibited the cytopathic effect, reduced viral protein and RNA levels in infected cells, and increased the survival rate of HCoV-OC43-infected suckling mice. Mechanistically, 4HCH targets the early stages of viral infection by binding to the epidermal growth factor receptor (EGFR) and inhibiting the EGFR/AKT/ERK1/2 signaling pathway, thereby suppressing viral replication. Additionally, 4HCH significantly reduced the production of pro-inflammatory cytokines and chemokines in both HCoV-OC43-infected RD cells and a suckling mouse model. Our findings demonstrate that 4HCH exhibits potent antiviral activity both in vitro and in vivo, suggesting its potential as a therapeutic agent against human coronaviruses. This study highlights EGFR as a promising host target for antiviral drug development and positions 4HCH as a candidate for further investigation in the treatment of coronavirus infections.

Indexed as

Antiviral AgentsChalconesCoronavirus InfectionsCoronavirus OC43, HumanMAP Kinase Signaling SystemAnimalsCell LineDisease Models, AnimalErbB ReceptorsHumansMiceProto-Oncogene Proteins c-aktSignal TransductionVirus ReplicationAntiviral AgentsChalconesEGFR protein, humanErbB ReceptorsProto-Oncogene Proteins c-akt4-hydroxychalconeantiviral activityEGFREGFR/AKT/ERK1/2 signaling pathwayflavonoidshuman coronavirus

Identifiers

PMID40872743
PMCPMC12390396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.